<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940134</url>
  </required_header>
  <id_info>
    <org_study_id>B262</org_study_id>
    <nct_id>NCT00940134</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.</brief_title>
  <acronym>INGEAR-1</acronym>
  <official_title>INGEAR-1: Effects of INtravenous Infusions of PYY3-36 and GLP-1, as Monoinfusion and in Combination, on ad Libitum Energy Intake, Appetite Sensation, and Energy Expenditure in Healthy Obese Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of intravenous infusion of two
      gastrointestinal hormones, PYY3-36 and GLP-1, alone and in combination, on appetite in
      healthy obese men. The investigators hypothesize that an intravenous infusion of each hormone
      alone will decrease food intake at a buffet meal and decrease appetite, and that in
      combination, there will be a greater decrease in food intake and appetite compared to each
      hormone alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ad libitum energy intake</measure>
    <time_frame>Immediately following 3h IV infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure (ventilated hood technique).</measure>
    <time_frame>During 3h IV infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of glucose, insulin, C peptide, GIP, leptin, ghrelin, adiponectin, cholecystokinin</measure>
    <time_frame>Prior to, and 15, 30, 60, 90, 120, 180 mins during IV infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite sensation by visual analog scale</measure>
    <time_frame>Every 30 minutes during 3h IV infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying (paracetamol)</measure>
    <time_frame>At time=15, 30, 60, 90, 120, 180 mins during IV infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will receive a 3 hour IV infusion of saline while fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PYY3-36 + GLP-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PYY3-36</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PYY 3-36</intervention_name>
    <description>0.8 pmol/kg/min x 3 hours</description>
    <arm_group_label>PYY3-36 + GLP-1</arm_group_label>
    <arm_group_label>PYY3-36</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>1.0 pmol/kg/min x 3 hours</description>
    <arm_group_label>PYY3-36 + GLP-1</arm_group_label>
    <arm_group_label>GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>saline infusion x 3 hours</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men age 18-50 years

          -  BMI â‰¥30

          -  healthy

        Exclusion Criteria:

          -  Diabetes mellitus

          -  psychological illness

          -  on special diets (eg vegetarian, Atkins)

          -  weight change of &gt;3kg within the 2 months prior to screening

          -  Hypothalamic or genetic aetiology of obesity

          -  diagnosed cancer

          -  chronic illness or disease

          -  Eating disorder (anorexia or bulimia)

          -  smoking

          -  substance abuse

          -  Use of any prescription or over the counter medication that can affect metabolism

          -  Excessive intake of alcohol (&gt;7 drinks/week)

          -  Excessive intake of caffeine (&gt;300 mg/day)

          -  High level of physical activity (&gt;10 hours/week)

          -  Lack of desire or willingness to take part in and follow study protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaj T Gregersen, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>AAstrup</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>incretins</keyword>
  <keyword>appetite regulation</keyword>
  <keyword>GLP-1</keyword>
  <keyword>PYY</keyword>
  <keyword>ad libitum energy intake</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

